A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

Background: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidity, there remains an unmet need for further treatme...

Full description

Bibliographic Details
Main Authors: Matthew Winter, Rob Coleman, Jessica Kendall, Carlo Palmieri, Chris Twelves, Sacha Howell, Iain MacPherson, Caroline Wilson, Kash Purohit, Jacqui Gath, Christine Taylor, Richard Eastell, Geraldine Murden, Sarah R. Brown, Emma Rathbone, Janet Brown
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Journal of Bone Oncology
Subjects:
Radium-223
Capecitabine
Bone metastases
Bone turnover markers
Breast cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S221213742200032X

Internet

http://www.sciencedirect.com/science/article/pii/S221213742200032X

Similar Items